CA3039322A1 - Immunogenic compounds for cancer therapy - Google Patents

Immunogenic compounds for cancer therapy Download PDF

Info

Publication number
CA3039322A1
CA3039322A1 CA3039322A CA3039322A CA3039322A1 CA 3039322 A1 CA3039322 A1 CA 3039322A1 CA 3039322 A CA3039322 A CA 3039322A CA 3039322 A CA3039322 A CA 3039322A CA 3039322 A1 CA3039322 A1 CA 3039322A1
Authority
CA
Canada
Prior art keywords
cancer
antigenic peptide
peptide
seq
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3039322A
Other languages
English (en)
French (fr)
Inventor
Laurent Chene
Alban MATHIEU
Matthieu PICHAUD
Francesco STROZZI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterome SA
Original Assignee
Enterome SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome SA filed Critical Enterome SA
Publication of CA3039322A1 publication Critical patent/CA3039322A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3039322A 2016-10-07 2017-10-09 Immunogenic compounds for cancer therapy Pending CA3039322A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16192948.4 2016-10-07
EP16192948 2016-10-07
PCT/EP2017/075673 WO2018065623A2 (en) 2016-10-07 2017-10-09 Immunogenic compounds for cancer therapy

Publications (1)

Publication Number Publication Date
CA3039322A1 true CA3039322A1 (en) 2018-04-12

Family

ID=57123864

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3039322A Pending CA3039322A1 (en) 2016-10-07 2017-10-09 Immunogenic compounds for cancer therapy

Country Status (9)

Country Link
US (2) US11478537B2 (OSRAM)
EP (1) EP3522915A2 (OSRAM)
JP (3) JP7116278B2 (OSRAM)
KR (2) KR102686875B1 (OSRAM)
CN (2) CN117801066A (OSRAM)
AU (3) AU2017339577B2 (OSRAM)
CA (1) CA3039322A1 (OSRAM)
IL (3) IL296165B2 (OSRAM)
WO (1) WO2018065623A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102686875B1 (ko) 2016-10-07 2024-07-19 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
EP3522917A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
CA3094262A1 (en) 2018-04-11 2019-10-17 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
CA3153470A1 (en) * 2019-11-15 2021-05-20 Laurent Chene Antigenic peptides for prevention and treatment of b-cell malignancy
KR20230040345A (ko) * 2020-07-13 2023-03-22 오레곤 헬스 앤드 사이언스 유니버시티 면역 반응을 유도하기 위한 면역원성 구축물, 조성물 및 방법
CN112010960A (zh) * 2020-09-10 2020-12-01 热休(厦门)细胞生物科技有限公司 一种肿瘤抗原复合物体外致敏dc、t细胞获得肿瘤特异性杀伤细胞ctl及其制备方法
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO2004031211A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
WO2001000225A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
JP2003530083A (ja) * 1999-12-10 2003-10-14 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ＨＥＲ２／ｎｅｕに対する細胞性免疫応答の誘導
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
MXPA02008219A (es) * 2000-02-23 2005-06-30 Epimmune Inc Peptidos que enlazan hla y sus usos.
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2002254348B2 (en) 2002-03-22 2007-12-06 The Penn State Research Foundation Cancer immunotherapy
CN1954217B (zh) * 2004-02-06 2013-05-08 国立健康与医学研究所 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
JP2010512402A (ja) 2006-12-11 2010-04-22 ワイス エルエルシー Ｉｌ−１３関連障害を治療するための方法および組成物ならびにその治療をモニター観察するための方法
JP2010190572A (ja) * 2007-06-01 2010-09-02 Sapporo Medical Univ ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
SG183717A1 (en) 2007-08-20 2012-09-27 Oncotherapy Science Inc Foxm1 peptide and medicinal agent comprising the same
EP2324057B1 (en) 2008-08-12 2018-03-21 MSD Italia S.r.l. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
AU2011293522B2 (en) 2010-08-24 2015-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
ES2887580T3 (es) 2012-03-19 2021-12-23 Stemline Therapeutics Inc Métodos para el tratamiento y seguimiento del estado del cáncer
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
SI3536334T1 (sl) 2012-05-16 2021-11-30 Stemline Therapeutics Inc. Cepiva proti raku, ki ciljajo na rakave matične celice
US20140141044A1 (en) * 2012-11-12 2014-05-22 Dana-Farber Cancer Institute, Inc. Cord Colitis Syndrome Pathogen
US9758807B2 (en) 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides
CN105008380B (zh) 2012-12-06 2018-01-23 维多利亚联结有限公司 缀合化合物
KR20160016725A (ko) * 2014-08-05 2016-02-15 주식회사 유영제약 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
US10414812B2 (en) 2015-02-16 2019-09-17 The Trustees Of The University Of Pennsylvania Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
WO2016159875A1 (en) * 2015-03-31 2016-10-06 Agency For Science, Technology And Research Method for antigen loading of dendritic cells and vaccine
EP3464630A1 (en) 2016-05-23 2019-04-10 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods of diagnosing cancer using cancer testis antigens
EP3522917A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
KR102686875B1 (ko) 2016-10-07 2024-07-19 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
WO2019072871A2 (en) 2017-10-09 2019-04-18 Enterome S.A. MICROBIOTIC SEQUENCE VARIANTS OF ANTIGENIC EPITOPES ASSOCIATED WITH A TUMOR
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
CA3094262A1 (en) 2018-04-11 2019-10-17 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
EP4045150B1 (en) 2019-10-16 2025-11-26 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
CA3153470A1 (en) 2019-11-15 2021-05-20 Laurent Chene Antigenic peptides for prevention and treatment of b-cell malignancy

Also Published As

Publication number Publication date
WO2018065623A2 (en) 2018-04-12
AU2017339577A1 (en) 2019-05-02
AU2022200872B2 (en) 2023-06-29
EP3522915A2 (en) 2019-08-14
US20200113983A1 (en) 2020-04-16
IL296165B1 (en) 2023-06-01
US11478537B2 (en) 2022-10-25
US12263210B2 (en) 2025-04-01
AU2023222999A1 (en) 2023-09-21
CN110022893B (zh) 2023-12-29
IL265751B (en) 2022-10-01
IL265751A (en) 2019-05-30
JP7331207B2 (ja) 2023-08-22
JP2023156414A (ja) 2023-10-24
CN117801066A (zh) 2024-04-02
IL302345A (en) 2023-06-01
AU2022200872A1 (en) 2022-03-03
IL296165A (en) 2022-11-01
WO2018065623A3 (en) 2018-05-31
KR20190066028A (ko) 2019-06-12
AU2017339577B2 (en) 2021-12-02
KR102686875B1 (ko) 2024-07-19
CN110022893A (zh) 2019-07-16
JP2022120137A (ja) 2022-08-17
JP7116278B2 (ja) 2022-08-10
KR102622188B1 (ko) 2024-01-05
KR20240007316A (ko) 2024-01-16
JP7648311B2 (ja) 2025-03-18
AU2023222999B2 (en) 2025-07-24
IL296165B2 (en) 2023-10-01
IL302345B2 (en) 2024-12-01
IL302345B1 (en) 2024-08-01
JP2019534884A (ja) 2019-12-05
IL265751B2 (en) 2023-02-01
US20230201322A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US12263210B2 (en) Immunogenic compounds for cancer therapy
JP7670445B2 (ja) 癌の予防及び治療のための抗原性ペプチド
US12059460B2 (en) Immunogenic compounds for cancer therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220912

EEER Examination request

Effective date: 20220912

EEER Examination request

Effective date: 20220912

EEER Examination request

Effective date: 20220912